SDF1 3A遗传多态性对高血压患者应用卡托普利疗效的影响(英文)  

Impact of genetic polymorphism of SDF1 3A on efficacy of captopril in Chinese patients with essential hypertension

作　　者：严研[1,2] 宁晨[3] 周环[1] 杨锡恒[1] 杨天[山仑][1] 刘昭前[4] 

机构地区：[1]中南大学湘雅医院心血管内科,长沙410008 [2]首都医科大学附属北京安贞医院抢救中心,北京100029 [3]中南大学湘雅医院泌尿科,长沙410008 [4]中南大学临床药理研究所,遗传药理学湖南省重点实验室,长沙410078

出　　处：《中南大学学报（医学版）》2010年第6期549-556,共8页Journal of Central South University ：Medical Science

基　　金：supported by the Huge Project to Boost Chinese Drug Development(2009ZX09304-003);National Natural Science Foundation of China(30873089)

摘　　要：目的:研究SDF1 3A基因多态性与高血压病易感性和高血压患者应用卡托普利疗效的关系。方法:运用PCR-RFLP对214名高血压患者和228名正常健康个体进行SDF1 3A基因分型。在39名不同SDF1 3A基因型的个体中, 13名高血压患者同时口服卡托普利(25 mg/d)和尼群地平(30 mg/d) , 12名高血压患者仅口服尼群地平(30 mg/d) ,所有患者连续服药8周以上,14名正常健康个体没有服任何药物。检测所有受试者的血压变化,以此评估药物的治疗效果。结果:在卡托普利和尼群地平治疗后,SDF1 3AAA+AG基因型或GG基因型的高血压患者中血浆SDF-1水平显著高于正常健康对照组(P<0.05) ;AA基因型携带者与GG基因型相比较,有较低水平的血浆总蛋白和球蛋白(P<0.05 ) ;高血压患者经卡托普利治疗后,AA +AG基因型个体的收缩压降低效果明显好于GG基因型个体(P<0.05)。结论:SDF1 3A遗传多态性可以影响中国汉族高血压患者应用卡托普利的疗效。Objective To explore the association of SDF1 3A genetic polymorphism with susceptibility of essential hypertension and captopril efficacy in patients with essential hypertension.Methods A total of 214 patients with essential hypertension and 228 healthy controls were genotyped for SDF1 3A polymorphism by polymerase chain reaction-restriction fragment length polymorphism assay.Among 39 subjects with different SDF1 3A of genotypes,13 hypertensive patients simultaneously took oral captopril （25 mg/d） and nitrendipine （30 mg/d）,and 12 patients orally received nitrendipine alone for 8 consecutive weeks,and 14 healthy controls did not take any agents.The blood pressure of all subjects was measured to evaluate the therapeutic efficacy.Results There was a significant difference in the plasma SDF-1 level in individuals with AA＋AG genotypes or GG genotypes of SDF1 3A treated with nitrendipine plus captopril compared with healthy control （P0.05）.Carriers with AA genotypes of SDF1 3A had lower total protein and globulin than those with GG genotypes （P0.05）.After captopril treatment,hypertensive patients with AA＋AG genotypes had bigger attenuated systolic blood pressure compared with those with GG genotypes （P0.05）.Conclusion Genetic polymorphism of SDF1 3A could influence the therapeutic efficacy of captopril in Chinese hypertensive patients.

关 键 词：高血压 SDF-1 SDF1 3A基因多态性 卡托普利 尼群地平 

分 类 号：R544.1[医药卫生—心血管疾病]